These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 29057176)

  • 1. The Effect of Conversion from a Calcineurin Inhibitor to Sirolimus on Skin Cancer Reduction in Post-renal Transplantation Patients.
    Smith A; Niu W; Desai A
    Cureus; 2017 Aug; 9(8):e1564. PubMed ID: 29057176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.
    Flechner SM; Kobashigawa J; Klintmalm G
    Clin Transplant; 2008; 22(1):1-15. PubMed ID: 18217899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
    Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recurrent non-melanoma skin cancer: remission of field cancerization after conversion from calcineurin inhibitor- to proliferation signal inhibitor-based immunosuppression in a cardiac transplant recipient.
    Signorell J; Hunziker T; Martinelli M; Koestner SC; Mohacsi PJ
    Transplant Proc; 2010 Nov; 42(9):3871-5. PubMed ID: 21094874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of proliferation signal inhibitors in non-melanoma skin cancer following renal transplantation.
    de Fijter JW
    Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i23-6. PubMed ID: 17456615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic Review of Calcineurin Inhibitors and Incidence of Skin Malignancies after Kidney Transplantation in Adult Patients: A Study of 309,551 Cases.
    Kulbat A; Richter K; Stefura T; Kołodziej-Rzepa M; Kisielewski M; Wojewoda T; Wysocki WM
    Curr Oncol; 2023 Jun; 30(6):5727-5737. PubMed ID: 37366913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
    Tönshoff B; Höcker B
    Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sirolimus for Secondary Prevention of Skin Cancer in Kidney Transplant Recipients: 5-Year Results.
    Dantal J; Morelon E; Rostaing L; Goffin E; Brocard A; Tromme I; Broeders N; Del Marmol V; Chatelet V; Dompmartin A; Kessler M; Serra A; Hofbauer GFL; Kamar N; Pouteil-Noble C; Kanitakis J; Roux A; Decullier E; Euvrard S;
    J Clin Oncol; 2018 Sep; 36(25):2612-2620. PubMed ID: 30016177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function.
    Watson CJ; Gimson AE; Alexander GJ; Allison ME; Gibbs P; Smith JC; Palmer CR; Bradley JA
    Liver Transpl; 2007 Dec; 13(12):1694-702. PubMed ID: 18044728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcineurin inhibitor minimization using sirolimus leads to improved renal function in pediatric heart transplant recipients.
    Chinnock TJ; Shankel T; Deming D; Cutler D; Sahney S; Fitts J; Chinnock RE
    Pediatr Transplant; 2011 Nov; 15(7):746-9. PubMed ID: 21883751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
    Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy.
    Tsai MK; Wu FL; Lai IR; Lee CY; Hu RH; Lee PH
    Int J Artif Organs; 2009 Jun; 32(6):371-80. PubMed ID: 19670189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. De novo cancer avoidance after renal transplantation: A case-control study on low-dose sirolimus combined with a calcineurin inhibitor.
    Chen KH; Lee CY; Wu FL; Yang CY; Yeh CC; Hu RH; Tsai MK
    J Formos Med Assoc; 2015 Jun; 114(6):526-31. PubMed ID: 25843527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical insights for cancer outcomes in renal transplant patients.
    Alberú J
    Transplant Proc; 2010 Nov; 42(9 Suppl):S36-40. PubMed ID: 21095450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sirolimus and secondary skin-cancer prevention in kidney transplantation.
    Euvrard S; Morelon E; Rostaing L; Goffin E; Brocard A; Tromme I; Broeders N; del Marmol V; Chatelet V; Dompmartin A; Kessler M; Serra AL; Hofbauer GF; Pouteil-Noble C; Campistol JM; Kanitakis J; Roux AS; Decullier E; Dantal J;
    N Engl J Med; 2012 Jul; 367(4):329-39. PubMed ID: 22830463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mycophenolate and sirolimus as calcineurin inhibitor-free immunosuppression improves renal function better than calcineurin inhibitor-reduction in late cardiac transplant recipients with chronic renal failure.
    Groetzner J; Kaczmarek I; Schulz U; Stegemann E; Kaiser K; Wittwer T; Schirmer J; Voss M; Strauch J; Wahlers T; Sohn HY; Wagner F; Tenderich G; Stempfle HU; Mueller-Ehmsen J; Schmid C; Vogeser M; Koch KC; Reichenspurner H; Daebritz S; Meiser B; Reichart B;
    Transplantation; 2009 Mar; 87(5):726-33. PubMed ID: 19295318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-melanoma skin cancer outcomes in kidney transplant recipients converted from calcineurin inhibitors to mTOR inhibitors: a systematic review.
    Olszewska B; Imko-Walczuk B; Dębska-Ślizień A
    Postepy Dermatol Alergol; 2023 Apr; 40(2):187-193. PubMed ID: 37312910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conversion from calcineurin inhibitors to sirolimus reduces vascularization and thickness of post-transplant cutaneous squamous cell carcinomas.
    Rival-Tringali AL; Euvrard S; Decullier E; Claudy A; Faure M; Kanitakis J
    Anticancer Res; 2009 Jun; 29(6):1927-32. PubMed ID: 19528449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus.
    Fairbanks KD; Eustace JA; Fine D; Thuluvath PJ
    Liver Transpl; 2003 Oct; 9(10):1079-85. PubMed ID: 14526403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity.
    Kushwaha SS; Khalpey Z; Frantz RP; Rodeheffer RJ; Clavell AL; Daly RC; McGregor CG; Edwards BS
    J Heart Lung Transplant; 2005 Dec; 24(12):2129-36. PubMed ID: 16364861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.